Safety studies conducted on pecan shell fiber, a food ingredient produced from ground pecan shells  by Dolan, Laurie et al.
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Use  of pecan  shell  ﬁber  in  human  food  is presently  limited,  but could  increase  pending  demonstration  of
safety.  In a 91-day  rat study,  pecan  shell  ﬁber  was  administered  at dietary  concentrations  of  0  (control),
50 000,  100  000 or 150 000  ppm.  There  was  no  effect  of  the  ingredient  on  body  weight of males  or  females
or  food  consumption  of females.  Statistically  signiﬁcant  increases  in  food  consumption  were  observed
throughout  the  study  in 100  000  and  150 000 ppm  males,  resulting  in intermittent  decreases  in food  efﬁ-
ciency  (150  000  ppm  males  only)  that  were  not  biologically  relevant.  All  animals  survived  and  no adverse
clinical  signs  or functional  changes  were  attributable  to the  test  material.  There  were  no  toxicologically
relevant  changes  in  hematology,  clinical  chemistry  or urinalysis  parameters  or organ  weights  in  ratsiber
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ingesting  pecan  shell  ﬁber.  Any  macroscopic  or microscopic  ﬁndings  were  incidental,  of normal  variation
and/or  of minimal  magnitude  for test  substance  association.  Pecan  shell  ﬁber  was  non-mutagenic  in  a
bacterial  reverse  mutation  test  and  non-clastogenic  in  a  mouse  peripheral  blood micronucleus  test.  Based
on these  results,  pecan  shell  ﬁber  has  an  oral  subchronic  (13-week)  no  observable  adverse  effect  level
(NOAEL)  of  150 000  ppm  in  rats  and  is  not  genotoxic  at the  doses  analyzed.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
The typical American consumes approximately 15 g ﬁber/day,
ell under the recommended 14 g/1000 calories, or 25 g/day for
omen and 38 g/day for men  [17]. Health beneﬁts associated with
igh ﬁber intakes include lower risk for developing coronary heart
isease, stroke, hypertension, diabetes, obesity, and certain gas-
rointestinal diseases [13,3,16]. In an attempt to increase the ﬁber
ontent of the diet, developers of food ingredients have created new
ber ingredients, some of which are produced by genetically mod-
ﬁed organisms. However, due to increased demand by consumers
or foods containing “natural” ingredients, there is an increased
eed for new ﬁber ingredients from “natural” sources.
Pecans, inclusive of several varieties of Carya illinoensis,  are
mong the most preferred of all nuts and an economically impor-
ant crop in the United States [5]. In 2014, approximately 264
illion pounds of pecan nuts (in-shell) were produced in the United
∗ Corresponding author at: Burdock Group, 859 Outer Road, Orlando, FL 32814,
nited States. Fax: +1 407 802 1405.
E-mail address: ldolan@burdockgroup.com (L. Dolan).
ttp://dx.doi.org/10.1016/j.toxrep.2015.11.011
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).States [18]. Pecans are often sold without shells, which are removed
during processing and often discarded. Based on a 50% shell-out
ratio (ratio of kernel weight to the in-shell nut weight) [10], approx-
imately 132 million pounds of pecan shells are produced by the US
pecan industry per year. Pecan shell ﬁber (also known as pecan
shell ﬂour or ground pecan shells) is a food ingredient produced
from shells of pecans, excluding the husks and nut kernels. Pecan
shell ﬁber is predominantly composed of insoluble ﬁber (cellulose,
lignin and hemicellulose) and contains small amounts of fat (<4%)
and protein (<3%). It also contains approximately 4.5% polyphenols
and 10% proanthocyanidins, molecules recognized for antioxidant
activity [7]. Therefore, pecan shell ﬁber has potential as both a ﬁber
ingredient and antioxidant in food formulations.
The American Association of Feed Control Ofﬁcials (AAFCO)1
includes Ground Pecan Shells (deﬁnition 60.110) in the 2015 ofﬁ-
cial publication of animal feed ingredients [1] as a source of ﬁber.
Although pecan shell ﬁber is Generally Recognized as Safe (GRAS)
for use as a “natural” ﬂavor complex for meat products (at a maxi-
1 An association which currently provides input to the FDA on the safety and
quality of feed ingredients
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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um  level of 3000 ppm (0.3%)) [19], pecan shell ﬁber is not GRAS for
ther purposes. Under section 201(s) of the Food Drug and Cosmetic
ct, the use of a substance, rather than the substance itself, is eligi-
le for a GRAS determination [9]. Although humans may  have been
ngesting small amounts of pecan shell ﬁber in the past, they have
ot been eating the ingredient at the considerably higher levels
xpected when used as a source of ﬁber. To support a higher level of
onsumption in humans, safe consumption of high levels of pecan
hell ﬁber must be demonstrated in experimental animals. Geno-
oxicity studies should also be conducted because the potential for
enotoxicity due to small levels of contaminants would increase
ith higher levels of consumption. This publication presents results
f a bacterial reverse mutation test, an in vivo mouse micronucleus
est and a 13-week feeding study in rats that were conducted to
xpand the use of pecan shell ﬁber in human food. A search of pub-
icly available information indicated that studies of this nature have
ot been previously conducted for pecan shell ﬁber.
. Materials and methods
.1. Test articles
One batch of pecan shell ﬁber (Southeastern Reduction Com-
any, Valdosta, GA) was used for the subchronic oral toxicity
tudy (181L21) and another batch for the genetic toxicity stud-
es (119L22). Both batches of test substance complied with the
anufacturer’s speciﬁcations.
The positive control mutagens utilized in the bacterial reverse
utation assay were: 4-nitro-o-phenylene-diamine (4-NOPD)
Fluka), sodium azide (NaN3) (Sigma), 2-aminoanthracene (2-AA)
Aldrich) and methylmethanesulfonate (MMS)  (Sigma). The S9 liver
icrosomal fraction was prepared at Euroﬁns BioPharma Prod-
ct Testing Munich GmbH (Euroﬁns Munich), from male Wistar
ats induced orally with phenobarbital (80 mg/kg bw)  and -
aphthoﬂavone (100 mg/kg bw)  for three consecutive days. Media
nd Vogel-Bonner Medium E agar plates were prepared at Euroﬁns
unich or obtained from an appropriate supplier.
The positive control substance for the micronucleus study was
yclophosphamide (Sigma), dissolved in physiological saline. The
olution was stored at ≤15 ◦C and thawed on the day of use.
.2. Animals and organisms
Male and female Sprague-Dawley (SD) rats used in the 90-day
tudy were obtained from Charles River Laboratories (Raleigh, NC)
nd shipped to the study site (Product Safety Labs, Dayton, NJ). The
nimals were acclimated for six days prior to testing, and were
even to eight weeks old at study initiation. Animals were housed
ndividually in suspended stainless steel cages, per standard prac-
ice of the laboratory. The animal room was maintained under a
2 h light/dark cycle, 19–23 ◦C and 38–60% relative humidity. Lit-
er paper placed underneath the cages was changed at least three
imes per week. Rats were supplied basal diet (Open Standard Diet
11112221NM, Research Diets Inc., New Brunswick, NJ) and ﬁl-
ered tap water ad libitum except for the before study termination,
hen food was withdrawn. The basal diet consisted of approxi-
ately 60% carbohydrates, 17% protein, 7% fat (added fat as soybean
il), and 9% ﬁber.
Animals were selected for use in the study based on adequate
ody weight gain, freedom from clinical signs of disease or injury
aside from two animals with minor ophthalmologic ﬁndings) and a
ody weight within ±20% of the mean within a sex. Rats used in the
tudy were randomly distributed into treatment groups according
o stratiﬁcation by body weight. All animals were fasted overnight
rior to blood collection. Serum samples from three animals thatports 3 (2016) 87–97
were housed with study animals but were not part of the study
were evaluated for the absence of common rat pathogens (Rat par-
vovirus, Toolan’s H-1 Virus, Kilham Rat Virus, Rat Minute Virus,
Parvovirus NS-1, Rat Coronavirus, Rat Theilovirus, and Pneumocys-
tis carinii)  on the last day of the test period. Because the sentinel
samples were negative for all pathogens evaluated, the study ani-
mals were deemed healthy and reasonably free of common rat
pathogens.
Male and female young, healthy adult NMRI mice (minimum
seven weeks of age) used in the micronucleus study were sup-
plied by Charles River, 97633 Sulzfeld, Germany and acclimated
for at least ﬁve days before use. The weight variation of the ani-
mals did not exceed ± 20% of the mean weight of each sex. Animals
were housed ﬁve/sex/cage in IVC, Type II L polysulfone cages with
Altromin saw ﬁber bedding (Altromin Spezialfutter GmbH, Lage,
Germany), in a room maintained under a 12 h light/dark cycle,
22 ± 3 ◦C and 55 ± 10% relative humidity. Food (Altromin 1324
Maintenance Diet) and tap water were freely available to the mice
except for a four hour period before the ﬁrst dose, during dosing,
and a two  to three hour period after the last dose of test material
or vehicle.
Bacterial strains Salmonella typhimurium TA98, TA100, TA1535
and TA1537 and Escherichia coli WP2uvrA were used for the muta-
genicity study. S. typhimurium TA 98 and TA 1535 and E. coli strain
WP2uvrA were obtained from MOLTOX, INC., NC 28607, USA. S.
typhimurium TA100 and TA 1537 were obtained from Xenometrix
AG, Allschwil, Switzerland. Stock cultures were stored in ampoules
with nutrient broth (OXOID) supplemented with dimethyl sul-
foxide (DMSO) (approximately 8% volume/volume) over liquid
nitrogen. Bacterial suspensions were thawed, grown for 12 h at
37 ◦C in nutrient medium, and used at a concentration of approxi-
mately 1 × 109 cells/ml.
2.3. Guidelines
The subchronic oral toxicity study was conducted in accordance
with Good Laboratory Practice (GLP) and OECD Guidelines for Test-
ing of Chemicals, Section 4, No. 408, “Health Effects, Repeated Dose
90-Day Oral Toxicity Study in Rodents”, dated September 21, 1998.
The bacterial reverse mutation test was conducted in accor-
dance with the Ninth Addendum to OECD Guidelines for Testing
of Chemicals, Section 4, No. 471, “Bacterial Reverse Mutation Test”,
adopted July 21, 1997; Commission Regulation (EC) No. 440/2008
B.13/14: “Mutagenicity - Reverse Mutation Test Using Bacteria”,
dated May  30, 2008 and EPA Health Effects Test Guidelines, OPPTS
870.5100 “Bacterial Reverse Mutation Assay” EPA 712-C-98-247,
August 1998.
The experimental procedure used in the mouse micronucleus
assay complied with OECD Guideline No. 474 “Mammalian Ery-
throcyte Micronucleus Test”, adopted September 26, 2014.
2.4. Experimental design
2.4.1. Subchronic oral toxicity study
Groups of 10 rats/sex were administered 0, 50 000, 100 000 or
150 000 ppm pecan shell ﬁber in the diet for 91 days, for target
exposures of 0, 3571, 7143 and 10 714 mg/kg bw/day test sub-
stance, estimated for a 350 g rat consuming 25 g feed/day. The
concentrations were based on the results of a fourteen day dose
range ﬁnding study in rats. Test diets were prepared weekly by
thoroughly blending the test substance into the basal diet with a
high-speed mixer. All prepared test and control diets were stored
under refrigeration until use. At the initial, middle and ﬁnal diet
preparation, a sample of the test (neat) substance was  retained for
stability analysis. During the ﬁrst week of the study, samples from
each dietary concentration were taken at ﬁrst presentation of the
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iet and on Days 4, 7 and 10 to verify the stability of the test material
n the dietary matrix. Samples were collected from the top, mid-
le and bottom of the mixer during preparation of the initial diet
o evaluate the homogeneity of the test substance in the matrix.
amples of representative animal diets from the control, low, mid
nd high dose groups were also taken to verify concentrations in
est diets. All samples were stored frozen until analyzed. The con-
entration of the test material in the neat substance and diet was
easured using gallic acid (a substance present in the test mate-
ial) as a marker, and analyzed values were compared to expected
target) values based on the concentration of gallic acid in the test
ubstance and the amount added to the diet. Prior to sample anal-
sis, the suitability of the method of detection for gallic acid (high
erformance liquid chromatography) was demonstrated. Method
alidation included, but was not limited to, determination of lin-
arity, precision and accuracy. Commercially available gallic acid
Fluka Analytical, purity 97.9%) served as the reference standard.
Body weights were recorded prior to test initiation, weekly dur-
ng the study, and just prior to study termination. Body weight gain
as calculated for selected intervals and for the overall study. Food
onsumption was recorded weekly and food efﬁciency (mean daily
ody weight gain/mean daily food consumption) was  calculated.
he mean overall daily intake of pecan shell ﬁber was calculated
ased on results of analytical studies, food consumption and body
eight. The animals were observed at least twice daily for mortality
nd once per day for signs of gross toxicity. Detailed observations
f clinical condition were also performed weekly, generally on days
hat the animals were weighed.
.4.1.1. Ophthalmologic observations. Ophthalmic examinations
ere conducted on all animals during the acclimation period and
n Day 86 of the study. Mydriatic eye drops were administered
rior to ophthalmoscopy. All eyes were examined by focal illu-
ination, indirect ophthalmoscopy and, when indicated, slit-lamp
icroscopy.
.4.1.2. Functional observational battery/motor activity. A func-
ional observational battery (FOB) was performed on all animals
uring Week 12 of the study. Each rat was evaluated during han-
ling and while in an open ﬁeld for excitability, autonomic function,
ait and sensorimotor coordination (open ﬁeld and manipula-
ive evaluations), reactivity and sensitivity (elicited behavior) and
bnormal clinical signs including but not limited to convulsions,
remors, unusual or bizarre behavior, emaciation, dehydration and
eneral appearance. Forelimb and hind limb grip strength and foot
play measurements were also recorded. Rats were observed in
andom order and without the observer having knowledge of the
reatment group. Motor activity was monitored using an automated
hotobeam Activity System® (San Diego Instruments, Inc). Each
nimal was evaluated in a polycarbonate, solid bottom cage for a
ingle one hour phase, with photobeam counts accumulated over
ix 10 min  intervals.
.4.1.3. Urinalysis. During Week 13 (one day before urine and
lood collection) the animals were placed in metabolism cages after
 15 h fast. Urine samples were collected from each animal and
tored under refrigeration until analyzed for quality, color, clarity,
olume, sediment (microscopic), pH, glucose, speciﬁc gravity, pro-
ein, ketones, bilirubin, blood and urobilinogen by DuPont Haskell
lobal Centers for Health and Environmental Sciences (Newark,
E)..4.1.4. Hematology, clinical chemistry and serology. After urine col-
ection was completed, blood samples for hematology and clinical
hemistry were collected via sublingual bleeding under isoﬂurane
nesthesia, with the exception of samples for indices of coagulationports 3 (2016) 87–97 89
(prothrombin time (PTT) and active partial thromboplastin time
(APTT)), which were collected from the inferior vena cava. Blood
samples for hematology were placed in tubes containing K2EDTA
and stored under refrigeration until analysis by DuPont Haskell
Global Centers for Health and Environmental Sciences. Blood sam-
ples for clinical chemistry were collected into tubes that did not
contain a preservative and were centrifuged under refrigeration to
obtain serum. Serum was  stored at −80 ◦C and shipped frozen on
dry ice to DuPont Haskell Global Centers for Health and Environ-
mental Sciences for analysis.
Hematological parameters measured included red blood cell
count (RBC), hemoglobin concentration (HGB), hematocrit (HCT),
mean corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), red blood cell distribution width (RDW), mean corpuscu-
lar hemoglobin concentration (MCHC), absolute reticulocyte count
(ARET), platelet count (PLT), PTT, APTT, and total white blood
cell (WBC) and differential leukocyte count (absolute neutrophils
(ANEU), lymphocytes (ALYM), monocytes (AMON), basophils
(ABAS), large unstained cells (ALUC), hypersegmented neutrophils
(AHSN), immature lymphocytes (AIL), eosinophils (AEOS) and neu-
trophil bands (ABAN)).
Clinical chemistry analyses included aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), sorbital dehydro-
genase (SDH), alkaline phosphatase (ALKP), total bilirubin (BILI),
blood urea nitrogen (BUN), blood creatinine (CREA), total choles-
terol (CHOL), triglycerides (TRIG), fasting glucose (GLUC), total
serum protein (TP), albumin (ALB), globulin (GLOB), calcium (Ca),
chloride (Cl), inorganic phosphorus (IPHS), potassium (K), and
sodium (Na).
2.4.1.5. Pathology. At study termination (Day 92 for males and
Day 93 for females), all animals were euthanized by exsanguina-
tion from the abdominal aorta under isoﬂurane anesthesia. All
animals (including decedents) were subjected to a full necropsy,
which included examination of the external surface of the body,
all oriﬁces, and the thoracic, abdominal and cranial cavities and
their contents. The following organs were collected and weighed:
adrenals (combined), brain, epididymides, heart, kidneys (com-
bined), liver, spleen, thymus, ovaries (females, combined), testes
(males, combined) and uterus and oviducts (females). Following
weighing, these organs were preserved in 10% buffered formalin
(excepting the epididymides, testes, and eyes (with optic nerves)
which were preserved in modiﬁed Davidsons’ ﬁxative and stored in
ethanol) for possible future histopathological examination. Addi-
tional tissues that were collected from each animal at necropsy
and preserved in 10% neutral buffered formalin included all tissues
that contained gross lesions, accessory genital organs (prostate and
seminal vesicles), aorta, bone (femur), bone marrow (femur and
sternum), cecum, cervix, colon, duodenum, esophagus, Harderian
gland, ileum, jejunum, larynx, lungs, mammary gland, mesen-
teric and mandibular lymph nodes, nose with nasal turbinates,
pancreas, peripheral nerve (sciatic), pharynx, pituitary, rectum,
salivary glands, skeletal muscle, skin, spinal cord (cervical, mid-
thoracic, lumbar), sternum, stomach, thyroid/parathyroid, trachea,
urinary bladder and vagina.
The ﬁxed organs and tissues were processed, embedded in
parafﬁn, sectioned, stained with hematoxylin and eosin and
examined by light microscopy. Slide preparation was performed
by Histo-Scientiﬁc Research Laboratories (HSRL), and the tis-
sues, blocks, and slides were returned to Product Safety Labs
and examined by a board-certiﬁed pathologist. Histopathological
examinations were performed on the preserved organs and tis-
sues of all control and high dose animals. These examinations were
extended to tissues and organs from the low and intermediate
groups to further investigate any lesions discovered in the high
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ose animals (if present). Organs with macroscopic observations
ere evaluated histologically for all treatment groups.
.4.1.6. Statistical analyses. Means and standard deviations were
alculated for all quantitative data; data for males and females
ere analyzed separately. Statistical analysis was performed on
ll quantitative data for in-life (except motor activity measure-
ents) and organ weight parameters using Provantis® version 8,
ables and Statistics, Instem LSS, Staffordshire UK. Motor Activity
total movements) quantitative measurements were statistically
nalyzed using INSTAT Biostatistics, Graph Pad Software, San Diego,
A. Quantitative data were analyzed for homogeneity of variance
nd normality by Bartlett’s test or Levene’s test for homogeneity
nd Shapiro–Wilk’s test for normality. Data that were normally dis-
ributed and homogenous were analyzed using a one-way ANOVA,
ollowed by comparisons of the treated groups to control by Dun-
ett’s t-test for multiple comparisons. Motor activity data (overall
otal movements) was further analyzed using a Two-Way Repeated
easures analysis of variance (ANOVA) (SigmaStat version 2.03).
ata that were not normally distributed or homogenous were ana-
yzed using a Kruskal–Wallis non parametric ANOVA, followed by
 Dunn’s test. Data were evaluated at the p < 0.05 and p < 0.01 levels
f signiﬁcance, with p < 0.05 chosen as the minimum criterion for
tatistical signiﬁcance.
.4.2. Bacterial reverse mutation assay
The ability of pecan shell ﬁber to cause mutations was assessed
n a bacterial reverse mutation assay using a plate incorporation
ethod (Experiment 1) and preincubation method (Experiment 2).
 preliminary experiment to assess the potential toxicity of pecan
hell ﬁber was determined in S. typhimurium strains TA98 and
A100. Eight concentrations (ranging from 3.16 to 5000 g/plate)
ere tested for toxicity and solubility in three plates per strain. Tox-
city was assessed by a clearing or dimunition of the background
awn or a reduction in the number of revertants down to a mutation
actor of approximately ≤0.5 in relation to the solvent control. The
oncentrations used in the main experiment (10–5000 g/plate for
xperiment 1 and 3.16 to 2500 g/plate for Experiment 2) were
hosen based on the results of the pre-experiment.
Bacterial strains utilized in both experiments were S.
yphimurium tester strains TA98, TA100, TA1535 and TA1537 and
. coli WP2uvrA. Each assay was conducted in the presence and
bsence of metabolic activation with S9 mix  prepared from the
9 microsomal fraction of male rat liver. The test substance was
uspended homogenously in distilled water and added to plates
o achieve concentrations of 5000, 2500, 1000, 316, 100 and
1.6 g/plate. The positive controls in the absence of S9 mix  were
-nitro-o-phenylene-diamine (4-NOPD) for TA98 and TA1537,
odium azide (NaN3) for TA100 and TA1535 and methylmethane-
ulfonate (MMS)  for E. coli WP2uvrA. The positive control for all
acterial strains in the presence of S9 mix  was 2-aminoanthracene
2-AA) and the negative control for all strains in the presence or
bsence of S9 mix  was aqua dest (distilled water).
The following substances were mixed in a test tube and poured
ver the surface of a Vogel–Bonner Medium E agar plate with
% glucose: (1) the positive or negative control solutions or test
ormulations (0.1 ml  each); (2) 0.5 ml  of 0.2 M sodium phosphate
uffer (pH 7.4) or 0.5 ml  of the S9 mix  (for metabolic activation);
3) 0.1 ml  of bacterial suspension; and (4) 2 ml  of overlay agar.
hree plates were prepared per experimental condition. All plates
ere inverted and incubated at 37 ◦C for 48 h in the dark prior to
ounting. Each test plate was observed for growth inhibition or
he presence or absence of a precipitate, and revertant colonies
ere counted using a ProtoCol counter (Meintrup DWS  Laborgeräte
mbH). Tester strains with a low spontaneous mutation frequency
e.g., TA 1535 and 1537) and plates containing precipitates wereports 3 (2016) 87–97
also counted manually. The test material was considered to be
positive for mutagenicity when the numbers of revertant colonies
in the test article groups increased in a biologically signiﬁcant
manner (two times the control level for strains TA98, TA100 and
E. coli WP2uvrA and three times control for strains TA1535 and
TA1537) and/or the values increased in a dose-dependent man-
ner.
2.4.3. Mammalian micronucleus assay
In the micronucleus test, groups of mice (n = 5/sex) were dosed
with 3333 mg/kg bw test material suspended homogenously in cot-
tonseed oil three times daily (with two hours between each dose)
for a cumulative dose of 10 g/kg bw/day (the maximum tolerated
dose determined by a pre-experiment). The volume of each appli-
cation was 10 ml/kg bw. The vehicle control (cottonseed oil) was
administered by gavage three times per day to vehicle control mice
(ﬁve mice/sex), in an identical manner as the test group animals.
The positive control material (cyclophosphamide) was  adminis-
tered once intraperitoneally to a separate group of ﬁve mice/sex,
at a dose of 40 mg/kg bw. Samples of blood were taken from the
tail vein 44 h (all groups) and 68 h after the last dose (vehicle and
test material groups only). Blood cells were immediately ﬁxed in
ultracold methanol. At least 24 h after ﬁxation, blood cells were
washed in Hank’s balanced salt solution, and spun in a centrifuge at
600 × g for ﬁve min  (4 ◦C). After discarding the supernatant, blood
cell populations were identiﬁed using speciﬁc antibodies against
CD71 (expressed only at the surface of immature erythrocytes)
and CD61 (expressed at the surface of platelets). DNA content of
micronuclei was determined by the use of a DNA speciﬁc stain (pro-
pidium iodide, PI). Anti-CD71 and anti-CD61 antibodies were then
labeled with ﬂuorescein isothiocyanate (FITC) and phycoerythrin
(PE), respectively, and samples were analyzed using ﬂow cytom-
etry. Particles were differentiated using forward scatter (FSC) and
side scatter (SSC) parameters of the ﬂow cytometer. Fluorescence
intensities were recorded on the FL1, FL2 and FL3 channels for FITC,
PE and PI respectively. For all dose groups (including positive and
negative controls), 10 000 polychromatic erythrocytes per animal
were scored for the incidence of micronucleated immature ery-
throcytes. To detect a possible cytotoxic effect of the test item,
the ratio between immature and mature erythrocytes was deter-
mined. The result is expressed as relative PCE (rel. PCE = proportion
of polychromatic (immature) erythrocytes among total erythro-
cytes). The test substance was  judged positive if any test group
exhibited a statistically signiﬁcant increase in the frequency of
micronucleated immature erythrocytes compared with the concur-
rent negative control and the results are outside the distribution of
the historical negative control data (e.g., Poisson-based 95% control
limits).
3. Results
3.1. Subchronic oral toxicity study
3.1.1. Analysis of test substance
The neat test substance was  found to be stable under the con-
ditions of storage over the course of the study. Results of the gallic
acid analyses of the neat test substance from Day 0 (0.0032%) to
Day 84 (0.0038%) found a change of 18.8%, for an overall test sub-
stance stability of 118.8% over the course of the study, within the
range of analytical variance. The overall stability of pecan shell
ﬁber within the dietary mixtures based on gallic acid analyses at
Days 0 and 10 was 91.9%, 90.8%, and 96.4% of theoretical for dietary
concentrations of 50 000, 100 000, and 150 000 ppm (respectively).
Concentrations of gallic acid in feed at Day 0 averaged 105.3, 98.6,
and 99.9%; Day 42 averaged 95.7, 106.9, and 103.5%; and Day 84
L. Dolan et al. / Toxicology Reports 3 (2016) 87–97 91
Fig. 1. Mean body weights of male rats during the study. Standard deviations, which tended to be large for treated animals, are omitted for ﬁgure clarity.
ions, 
a
f
t
w
b
f
o
sFig. 2. Mean body weights of female rats during the study. Standard deviat
veraged 103.8%, 103.0%, and 109.5% of theoretical concentrations
or 50 000, 100 000, and 150 000 ppm pecan shell ﬁber (respec-
ively), demonstrating that target concentrations of the ﬁber in feed
ere obtained throughout the study. Analysis of the top, middle and
ottom of the 50 000, 100 000 or 150 000 ppm dietary preparations
or gallic acid showed percent relative standard deviations (%RSD)
f 7.43, 4.15 and 3.30 for each concentration (respectively), demon-
trating that the test substance was homogenously mixed into feed.which tended to be large for treated animals, are omitted for ﬁgure clarity.
Based on these analyses, the animals received the targeted daily
concentrations of pecan shell ﬁber.
3.1.2. In life observations
Mean body weights (Figs. 1 and 2) and body weight gain (data
not shown) of animals receiving pecan shell ﬁber were similar to
controls, with the exception of a statistically signiﬁcant increase
in body weight gain of females receiving 100 000 ppm test mate-
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Table 1
Mean food consumption of male and female rats during the study.
Day(s) relative to start date Control 50 000 mg/kg/day 100 000 mg/kg/day 150 000 mg/kg/day
Number of males 9 10 10 10
0  → 7 24.86 ± 2.43 26.26 ± 2.85 27.59 ± 2.62 28.21 ± 2.47 *
7 → 14 27.19 ± 3.11 28.60 ± 4.15 30.20 ± 2.69 30.89 ± 3.49
14  → 21 28.11 ± 2.86 29.80 ± 4.51 30.66 ± 3.32 32.10 ± 3.24
21  → 28 28.76 ± 2.95 29.84 ± 4.67 31.20 ± 3.53 32.30 ± 2.95
28  → 35 29.17 ± 2.52 29.94 ± 4.82 31.99 ± 3.56 32.94 ± 3.31
35  → 42 30.16 ± 2.76 30.91 ± 5.05 32.86 ± 4.22 34.17 ± 4.32
42  → 49 30.34 ± 2.76 30.14 ± 6.88 33.13 ± 3.74 34.10 ± 3.67
49  → 56 30.77 ± 2.58 30.74 ± 5.29 33.53 ± 3.59 34.87 ± 3.84
56  → 63 29.97 ± 1.49 29.21 ± 5.57 33.46 ± 3.63 33.09 ± 3.56
63  → 70 28.24 ± 1.73 29.36 ± 4.98 32.61 ± 3.51 * 33.27 ± 3.28 *
70 → 77 29.48 ± 2.13 28.33 ± 3.66 32.30 ± 4.03 33.57 ± 3.26 *
77 → 84 27.21 ± 1.71 29.20 ± 4.52 31.54 ± 3.24 * 31.61 ± 3.34 *
84 → 91 24.63 ± 1.91 27.21 ± 4.76 30.61 ± 5.94 ** 27.17 ± 2.78
0  → 91 28.04 ± 1.46 29.20 ± 4.31 31.67 ± 3.24 32.18 ± 3.03 *
Number of females 10 10 10 10
0  → 7 17.23 ± 1.77 17.94 ± 2.03 18.70 ± 1.95 18.50 ± 2.52
7  → 14 18.66 ± 3.08 17.83 ± 2.93 19.81 ± 4.14 19.79 ± 3.09
14  → 21 19.83 ± 3.79 18.24 ± 2.91 20.84 ± 4.87 20.06 ± 3.63
21  → 28 19.71 ± 3.71 18.34 ± 3.61 20.53 ± 3.68 19.44 ± 3.25
28  → 35 18.60 ± 3.63 18.44 ± 3.71 19.96 ± 4.11 19.66 ± 2.68
35  → 42 19.04 ± 3.29 18.74 ± 3.14 19.01 ± 3.63 19.07 ± 2.14
42  → 49 17.91 ± 3.09 17.17 ± 2.71 20.31 ± 4.61 18.84 ± 3.50
49  → 56 17.86 ± 2.64 17.43 ± 2.19 20.29 ± 3.58 19.06 ± 3.13
56  → 63 18.84 ± 3.72 18.14 ± 2.28 21.50 ± 4.45 19.33 ± 2.34
63  → 70 20.59 ± 7.47 17.93 ± 3.50 19.80 ± 3.68 18.33 ± 2.89
70  → 77 18.43 ± 3.90 16.49 ± 2.18 18.46 ± 3.68 18.37 ± 4.59
77  → 84 17.49 ± 3.30 15.96 ± 6.19 20.21 ± 5.06 18.66 ± 3.62
84  → 91 14.99 ± 1.97 15.50 ± 2.87 17.51 ± 2.87 16.94 ± 3.59
0  → 91 18.40 ± 2.60 17.55 ± 2.47 19.76 ± 3.30 18.93 ± 2.71
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* Signiﬁcantly different from control (Dunnett 2 Sided, p < 0.05).
** Signiﬁcantly different from control (Dunn 2 Sided, p < 0.01).
ial from Days 56–63 (p < 0.05). Overall (Days 0–91) and mean
aily food consumption for female rats exposed to the test sub-
tance were comparable with control values throughout the study
Table 1). There was no effect of pecan shell ﬁber on food efﬁciency
f females (data not shown). Statistically signiﬁcant increases
p < 0.01 or 0.05) in food consumption were reported on Days 63–70
nd 77–91 in 100 000 ppm males and on Days 0–7, 63–84, and over-
ll (Days 0–91) in 150 000 ppm males (Table 1). Feed efﬁciency
ecreased in males receiving 150 000 ppm on Days 0–7, 21–28,
nd overall (Days 0–91) (p < 0.01), but was not affected at lower
oncentrations (data not shown). The mean overall (Days 0–91)
aily intake of pecan shell ﬁber in male rats fed dietary concen-
rations of 50 000, 100 000 and 150 000 ppm was 2986.3, 6256.0,
nd 9947.5 mg/kg/day, respectively. For the same dietary concen-
rations, the mean overall daily intake of pecan shell ﬁber in female
ats was 3392.2, 7480.0, and 11 082.8 mg/kg/day, respectively.
There were no clinical signs attributed to administration of
ecan shell ﬁber. One control male died on Day 58 of an unde-
ermined cause. Ophthalmologic examinations of animals were
ormal, except for one female that had an iris coloboma and
ataract at study initiation and a cataract and chorioretinal scar-
ing at the end of the study. Results of functional observational,
orelimb/hindlimb grip strength, hindlimb foot splay and motor
ctivity assessments of test animals were comparable to con-
rols. Dietary exposure to 50 000, 100 000 or 150 000 ppm pecan
hell ﬁber did not induce any toxicologically signiﬁcant changes
n hematology or coagulation parameters (Table 2). While values
or MCH, MCHC and MCV  were lower than control and for RDW
ere higher than control in high dose males (p < 0.05), they were
ithin laboratory control historical ranges for Sprague-Dawley rats
15.3–20.7 pg MCH, 30.1–35.3 g/dL MCHC, 47.5–68.6 fL MCV  and
1.4–31.2% RDW). An increase in absolute basophils was observed
n females administered the high dose; however, the value waswithin the historical control range (0.0–0.7 103/L), and in light of
the absence of changes in other white blood cells, this change was
determined to be of no toxicological signiﬁcance. Other changes
that occurred in low or medium dose animals (decreased platelet
counts in mid-dose males, increased MCH  and MCV  in mid-dose
females and decreased RDW in low dose females (p < 0.05)). These
changes are toxicologically insigniﬁcant because they did not occur
in dose dependent manner, and are within laboratory control his-
torical ranges for Sprague-Dawley rats.
There were no changes in quantitative or qualitative urinaly-
sis parameters in males or females ingesting any concentration of
pecan shell ﬁber (data not shown). Minor but statistically signif-
icant differences in some clinical chemistry parameters (Table 3)
occurred (decreased BILI in high dose males, increased CHOL in
high dose females and decreased TG in mid  dose females, p < 0.05).
The changes in BILI and CHOL are incidental because the values
are within historical values (0.10–0.27 mg/dL BILI, 34–145 mg/dL
CHOL) and the changes were small in magnitude and not accom-
panied by any other corresponding clinical or histopathological
change. Although the TG value for low dose females was the only
TG value that differed signiﬁcantly from control, the TG values for
all groups of exposed females were reduced by 22–29%.
3.1.3. Necropsy observations
There were no statistically signiﬁcant changes in absolute or
relative organ weights of females, and no statistically signiﬁcant
changes in absolute organ weights of males (Table 4 Weights of
the spleen and liver relative to body weight (Table 4) or spleen to
relative to brain weight (data not shown) of high dose males were
signiﬁcantly lower than controls. Values were within historical con-
trol values (0.87–4.12 and 0.21–1.12 for spleen-to-body weight and
brain-to-body weight and 14.62–35.04 for liver-to-body weight)
and corresponding absolute organ weight changes or histopatho-
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Table  2
Hematology and coagulation data for rats administered pecan shell ﬁber for 91 days.
Parameter Control 50 000 mg/kg/day 100 000 mg/kg/day 150 000 mg/kg/day
Number of males 9 10 10 10
RBC  (106/L) 8.43 ± 0.40 8.53 ± 0.31 8.70 ± 0.43 8.73 ± 0.40
HGB  (g/dL) 15.4 ± 0.6 15.1 ± 0.3 15.4 ± 0.5 15.0 ± 0.2
HCT  (%) 45.8 ± 2.0 45.5 ± 1.1 46.0 ± 1.8 45.4 ± 1.0
MCH  (pg) 18.2 ± 0.5 17.7 ± 0.6 17.7 ± 0.4 17.2 ± 0.7**
MCHC (g/dL) 33.6 ± 0.4 33.2 ± 0.5 33.4 ± 0.3 33.1 ± 0.4*
MCV  (fL) 54.3 ± 1.2 53.3 ± 1.3 52.9 ± 1.1 52.1 ± 1.6*
RET (103/L) 182.4 ± 26.6 203.1 ± 52.0 190.2 ± 35.3 173.3 ± 26.4
PLT  (103/L) 1128 ± 147 1011 ± 138 963 ± 139* 1088 ± 125
RDW  (%) 12.7 ± 0.4 13.2 ± 0.9 13.5 ± 0.4 14.3 ± 0.8*
WBC  (103/L) 13.47 ± 3.65 12.54 ± 2.29 13.71 ± 3.53 11.69 ± 2.08
LYM  (103/L) 9.74 ± 2.76 9.68 ± 2.05 10.37 ± 3.20 8.82 ± 1.94
MON  (103/L) 0.38 ± 0.15 0.34 ± 0.10 0.36 ± 0.09 0.37 ± 0.10
NEU  (103/L) 2.98 ± 2.47 2.15 ± 1.15 2.50 ± 0.57 2.18 ± 0.98
EOS  (103/L) 0.23 ± 0.03 0.23 ± 0.05 0.29 ± 0.09 0.20 ± 0.06
BAS  (103/L) 0.07 ± 0.03 0.06 ± 0.03 0.09 ± 0.05 0.05 ± 0.03
LUC  (103/L) 0.08 ± 0.03 0.07 ± 0.03 0.08 ± 0.04 0.06 ± 0.03
PT  (s) 10.6 ± 0.3 10.6 ± 0.3 10.8 ± 0.3 10.9 ± 0.3
APTT  (s) 16.8 ± 1.7 16.8 ± 1.6 18.9 ± 2.8 18.2 ± 1.4
Number of females 10 10 10 10
RBC  (106/L) 8.35 ± 0.23 8.22 ± 0.41 8.18 ± 0.33 8.19 ± 0.23
HGB  (g/dL) 15.1 ± 0.6 15.1 ± 0.8 15.2 ± 0.5 15.2 ± 0.5
HCT  (%) 45.1 ± 1.7 44.3 ± 2.3 45.6 ± 1.8 45.2 ± 1.5
MCH  (pg) 18.1 ± 0.3 18.4 ± 0.4 18.6 ± 0.5* 18.5 ± 0.6
MCHC  (g/dL) 33.5 ± 0.4 34.1 ± 0.6 33.4 ± 0.4 33.6 ± 0.2
MCV  (fL) 54.1 ± 1.1 53.9 ± 1.5 55.8 ± 1.5* 55.1 ± 1.8
RET  (103/L) 147.9 ± 29.5 122.1 ± 29.4 155.5 ± 26.9 173.8 ± 38.2
PLT  (103/L) 979 ± 173 957 ± 160 1108 ± 96 979 ± 143
RDW  (%) 12.0 ± 0.1 11.7 ± 0.4** 11.8 ± 0.3 12.0 ± 0.3
WBC  (103/L) 6.89 ± 2.36 9.34 ± 3.41 7.74 ± 2.25 8.72 ± 2.39
LYM  (103/L) 5.48 ± 1.84 7.07 ± 2.52 5.95 ± 1.70 7.18 ± 2.24
MON  (103/L) 0.18 ± 0.09 0.28 ± 0.18 0.21 ± 0.09 0.19 ± 0.06
NEU  (103/L) 1.04 ± 0.49 1.77 ± 1.07 1.35 ± 0.58 1.13 ± 0.49
EOS  (103/L) 0.13 ± 0.05 0.14 ± 0.04 0.16 ± 0.04 0.14 ± 0.04
BAS  (103/L) 0.02 ± 0.01 0.03 ± 0.02 0.03 ± 0.01 0.03 ± 0.02*
LUC (103/L) 0.04 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.03
PT  (s) 10.2 ± 0.2 10.2 ± 0.2 10.2 ± 0.2 10.2 ± 0.2
APTT  (s) 17.3 ± 1.6 16.5 ± 1.7 16.8 ± 1.3 16.4 ± 1.6
Data are presented as mean ± standard deviation (SD).
APTT = activated partial thromboplastin time; BAS = basophils; dL = deciliter; EOS = eosinophils; fL = femtoliter; HCT = hematocrit; HGB = hemoglobin; LUC = large unstained
cells;  LYM = lymphocytes; MCH  = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; MCV  = mean corpuscular volume; mm3 = cubic
millimeter; MON  = monocytes; NEU = neutrophils; pg = picograms; PLT = platelets; PT = prothrombin time; RBC = erythrocytes; RDW = red blood cell distribution width;
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* Signiﬁcantly different from control by Dunnett Test (2 sided), p < 0.05.
** Signiﬁcantly different from control by Dunnett Test (non-parametric, 2 sided), p
ogical correlates did not occur; thus the statistical changes were
nterpreted to be of no toxicological relevance.
There were no macroscopic or microscopic ﬁndings related to
dministration of the test material. Fluid—ﬁlled uteri that were
oted in three to ﬁve females/group (including controls) cor-
esponded to cyclical dilation of the uterine lumen that was
ttributable to variation in the estrous cycle in individual ani-
als. The uterus of a high dose female presented with a 3 × 4 mm
rregular clear, tan cyst encompassing the right horn and adja-
ent cervix, which was ruled incidental and unrelated to test
ubstance exposure. A unilateral renal carcinoma was found in
ne mid  dose female, which was poorly demarcated, composed of
olyhedral cells, intensely basophilic, and exhibited a high nucleus-
o-cytoplasm ratio that focally formed tubular like structures. The
itotic index was approximately 5–7 mitoses per high power ﬁeld.
onsidering the lack of dose relationship, the single incidence, and
he absence of pre-neoplastic or neoplastic lesions in any other ani-
al  from this study, the renal tubular carcinoma observed in this
nimal was incidental and unrelated to the test substance expo-
ure. One mid  dose male exhibited a 2 × 3 mm,  irregular wall area,
ssociated with a white, 2 × 5 mm,  luminal concretion in the uri-
ary bladder. This ﬁnding did not have a microscopic correlate
nd was therefore incidental. All recorded microscopic ﬁndings5.
occurred sporadically or at a similar incidence in control and test
substance treated groups and were generally of the type commonly
seen in rats of this strain and age. Therefore, they were considered
incidental and unrelated to treatment.
3.2. Bacterial reverse mutagenic assay
As shown in Table 5, pecan shell ﬁber was nonmutagenic in the
bacterial reverse mutation assay. It did not induce any biologically
signiﬁcant or dose-dependent increases in the number of rever-
tant colonies in any strain tested in the absence or presence of
metabolic activation (i.e., S9 mix). Precipitation of the test item
was observed in all tester strains used in Experiment I at concen-
trations of 1000 g/plate and higher (with and without metabolic
activation) as well in all tester strains used in Experiment II at
concentrations of 2500 g/plate (with and without metabolic acti-
vation). In Experiment I toxic effects of the test substance were
observed in tester strain TA 1537 at concentrations of 2500 g/plate
and higher (without metabolic activation). In Experiment II, toxic
effects of the test item were noted in tester strain TA 100 at a con-
centration of 2500 g/plate (without metabolic activation) and in
tester strain TA 1537 at concentrations of 1000 g/plate and higher
(without metabolic activation). The assay was valid, as the posi-
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Table 3
Clinical chemistry data for rats administered pecan shell ﬁber for 91 days.
Parameter Control 50 000 mg/kg/day 100 000 mg/kg/day 150 000 mg/kg/day
Number of males 9 10 10 10
AST  (U/L)* 82 ± 10 85 ± 12 89 ± 20 80 ± 5
ALT  (U/L) 27 ± 13 25 ± 9 25 ± 6 25 ± 4
SDH  (U/L)* 7.7 ± 3.8 8.5 ± 1.5 6.3 ± 2.3 8.7 ± 2.1
ALKP  (U/L) 90 ± 19 83 ± 15 86 ± 22 81 ± 13
BILI  (mg/dL) 0.16 ± 0.03 0.17 ± 0.02 0.15 ± 0.03 0.13 ± 0.02**
BUN (mg/dL) 11 ± 2 13 ± 2 12 ± 1 10 ± 2
CREA  (mg/dL) 0.32 ± 0.04 0.30 ± 0.03 0.31 ± 0.03 0.30 ± 0.04
CHOL  (mg/dL) 75 ± 13 94 ± 38 97 ± 24 81 ± 20
TRIG  (mg/dL) 82 ± 28 82 ± 32 96 ± 45 79 ± 28
GLUC  (mg/dL) 123 ± 12 129 ± 19 136 ± 16 127 ± 15
TP  (g/dL) 6.4 ± 0.3 6.5 ± 0.4 6.4 ± 0.3 6.3 ± 0.1
ALB  (g/dL) 3.2 ± 0.1 3.2 ± 0.1 3.1 ± 0.1 3.1 ± 0.1
GLOB  (g/dL) 3.2 ± 0.3 3.3 ± 0.3 3.3 ± 0.2 3.2 ± 0.2
Ca  (mg/dL) 10.1 ± 0.3 10.1 ± 0.5 10.3 ± 0.5 10.0 ± 0.2
IPHS  (mg/dL)* 6.6 ± 0.4 6.4 ± 0.7 6.4 ± 0.5 6.2 ± 0.5
Na  (mmol/L) 146.4 ± 5.8 145.0 ± 6.7 148.1 ± 14.0 142.6 ± 5.1
K  (mmol/L) 5.09 ± 0.32 4.99 ± 0.51 5.23 ± 0.42 5.00 ± 0.21
Cl  (mmol/L) 106.2 ± 4.0 105.2 ± 4.0 107.5 ± 9.1 103.6 ± 3.5
Number of females 10 10 10 10
AST  (U/L) 63 ± 13 90 ± 50 86 ± 38 72 ± 23
ALT  (U/L) 16 ± 3 34 ± 38 28 ± 20 24 ± 12
SDH  (U/L) 6.8 ± 2.3 10.1 ± 4.2 10.6 ± 9.2 8.6 ± 3.9
ALKP  (U/L) 46 ± 9 63 ± 31 50 ± 22 52 ± 15
BILI  (mg/dL) 0.18 ± 0.03 0.19 ± 0.03 0.18 ± 0.02 0.17 ± 0.03
BUN  (mg/dL) 13 ± 3 13 ± 2 14 ± 3 12 ± 2
CREA  (mg/dL) 0.34 ± 0.04 0.39 ± 0.08 0.39 ± 0.05 0.35 ± 0.03
CHOL  (mg/dL) 82 ± 12 86 ± 17 77 ± 14 99 ± 15**
TRIG (mg/dL) 62 ± 19 44 ± 7** 47 ± 15 48 ± 12
GLUC  (mg/dL) 122 ± 6 126 ± 19 123 ± 18 125 ± 14
TP  (g/dL) 7.3 ± 0.5 7.0 ± 0.6 7.3 ± 0.5 7.3 ± 0.5
ALB  (g/dL) 4.0 ± 0.4 3.7 ± 0.5 4.0 ± 0.3 3.9 ± 0.3
GLOB  (g/dL) 3.3 ± 0.2 3.4 ± 0.3 3.3 ± 0.2 3.4 ± 0.3
Ca  (mg/dL) 10.5 ± 0.5 10.3 ± 0.8 10.5 ± 0.4 10.6 ± 0.3
IPHS  (mg/dL)* 5.0 ± 0.8 4.6 ± 0.7 4.8 ± 0.6 4.9 ± 0.6
Na  (mmol/L) 143.4 ± 6.8 146.3 ± 10.4 147.8 ± 6.1 148.2 ± 7.1
K  (mmol/L) 4.22 ± 0.26 4.16 ± 0.72 4.28 ± 0.37 4.34 ± 0.33
Cl  (mmol/L) 104.7 ± 5.4 106.9 ± 9.1 108.3 ± 4.4 108.0 ± 4.7
Data are presented as mean ± standard deviation (SD).
ALB = albumin; ALKP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BILI = total bilirubin; BUN = urea nitrogen; Ca =calcium;
CHOL  = cholesterol; Cl = chloride; CREA = creatinine; dL = deciliter;GLOB = globulin; GLUC = glucose; IPHS = inorganic phosphorus; K = potassium; mg  = milligrams;
m RIG = triglycerides; U = units.
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* Number of males: (Control: 7; 50 000 ppm: 7; 100 000 ppm: 9).
** Signiﬁcantly different from control by Dunnett Test (2 sided), p < 0.05.
ive controls showed a distinct increase in revertants meeting the
riteria for a positive response.
.3. Mammalian micronucleus assay
No animal deaths occurred in any of the dose groups in the
icronucleus test. A mild reduction of spontaneous activity and/or
alf eyelid closure were observed in the male group 30 min  and
ne hour after the last application of test material, which abated
y two hours. The mean relative PCE values for the 44 h negative
ontrols were 1.82% (male mice) and 0.80% (female mice). The cor-
esponding values for treated mice were 0.75% (males) and 1.35%
females). The values for relative PCE in the negative control group
ere within the historical limits (0.88–4.46%), except for the 44 h
alue for females, that was slightly below the lower limit. Since the
ariation was marginal and the animals did not show any clinical
igns the value was considered acceptable. The relative PCE value
or the treated male group was decreased relative to the concurrent
egative control but this decrease was not statistically signiﬁcant.
owever, the value was below the historical control limits. The
elative PCE value for the treated female group was  statistically
igniﬁcantly increased compared to the concurrent negative con-
rol. However, the value was within the historical control limits of
he negative control. For 68 h, the mean relative PCE values wereFig. 3. Incidences of micronucleated PCE [%] after 44 h (mean ± standard deviation).
2.10% (control males) and 1.46% (control females), 1.86% (treated
males) and 2.23% (treated females). The value in treated males was
decreased and the value in treated females was  increased com-
pared to the concurrent negative control, but the decreases were
not statistically signiﬁcant. Moreover, both values were within the
historical control limits of the negative control. The fact that relative
PCE values were slightly affected by in animals receiving the test
material results suggest that exposure of PCE to the test material
occurred.
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Table  4
Absolute organ weights (g) and relative organ to body weights (%) of rats administered pecan shell ﬁber for 91 days.
Control 50 000 mg/kg/day 100 000 mg/kg/day 150 000 mg/kg/day
Number of males 9 10 10 10
Body  weight (g) 603.7 ± 39.7 614.4 ± 106.1 637.5 ± 71.3 595.6 ± 60.1
Adrenals (g) 0.0628 ± 0.0076 0.0638 ± 0.0125 0.0706 ± 0.0105 0.0632 ± 0.0100
Adrenals/TBW (ratio) 0.1046 ± 0.0159 0.1043 ± 0.0151 0.1113 ± 0.0154 0.1070 ± 0.0189
Brain  (g) 2.341 ± 0.101 2.285 ± 0.106 2.289 ± 0.065 2.350 ± 0.083
Brain/TBW (ratio) 3.890 ± 0.263 3.798 ± 0.536 3.629 ± 0.397 3.981 ± 0.418
Epididymides (g) 1.499 ± 0.255 1.504 ± 0.168 1.586 ± 0.156 1.556 ± 0.085
Epididymides/TBW (ratio) 2.4871 ± 0.4261 2.5035 ± 0.4895 2.5079 ± 0.3011 2.6380 ± 0.3177
Heart  (g) 1.752 ± 0.164 1.778 ± 0.227 1.785 ± 0.192 1.772 ± 0.209
Heart/TBW (ratio) 2.914 ± 0.345 2.923 ± 0.292 2.805 ± 0.185 2.976 ± 0.183
Kidneys (g) 3.748 ± 0.379 3.729 ± 0.407 3.912 ± 0.527 3.773 ± 0.597
Kidneys/TBW (ratio) 6.215 ± 0.573 6.140 ± 0.599 6.149 ± 0.571 6.330 ± 0.701
Liver  (g) 15.201 ± 1.222 15.441 ± 3.592 15.804 ± 2.088 13.613 ± 1.939
Liver/TBW (ratio) 25.239 ± 2.200 25.019 ± 2.514 24.765 ± 1.584 22.795 ± 1.405*
Spleen (g) 1.040 ± 0.102 0.983 ± 0.222 1.033 ± 0.241 0.858 ± 0.120
Spleen/TBW (ratio) 1.727 ± 0.177 1.595 ± 0.188 1.616 ± 0.294 1.441 ± 0.152**
Testes (g) 3.592 ± 0.419 3.652 ± 0.368 3.806 ± 0.470 3.622 ± 0.259
Testes/TBW (ratio) 5.960 ± 0.680 6.053 ± 0.896 5.998 ± 0.685 6.120 ± 0.569
Thymus (g) 0.3463 ± 0.0914 0.4124 ± 0.0602 0.4020 ± 0.1200 0.3478 ± 0.0813
Thymus/TBW (ratio) 0.5735 ± 0.1458 0.6835 ± 0.1329 0.6328 ± 0.1883 0.5815 ± 0.1000
Number of females 10 10 10 10
Body  weight (g) 285.8 ± 28.4 276.0 ± 23.2 286.8 ± 41.4 275.6 ± 34.8
Adrenals (g) 0.0657 ± 0.0121 0.0609 ± 0.0104 0.0702 ± 0.0104 0.0623 ± 0.0170
Adrenals/TBW (ratio) 0.2285 ± 0.0248 0.2227 ± 0.0436 0.2477 ± 0.0413 0.2245 ± 0.0514
Brain  (g) 2.087 ± 0.084 2.077 ± 0.106 2.082 ± 0.102 2.046 ± 0.085
Brain/TBW (ratio) 7.376 ± 0.882 7.568 ± 0.680 7.371 ± 0.889 7.511 ± 0.799
Heart (g) 1.034 ± 0.100 0.996 ± 0.132 0.990 ± 0.103 0.974 ± 0.104
Heart/TBW (ratio) 3.623 ± 0.158 3.612 ± 0.393 3.485 ± 0.395 3.558 ± 0.366
Kidneys (g) 1.938 ± 0.172 1.877 ± 0.127 1.921 ± 0.171 1.906 ± 0.299
Kidneys/TBW (ratio) 6.800 ± 0.427 6.844 ± 0.725 6.803 ± 1.077 6.900 ± 0.436
Liver  (g) 7.500 ± 1.106 7.169 ± 0.694 7.409 ± 0.861 7.345 ± 0.995
Liver/TBW (ratio) 26.194 ± 2.139 26.128 ± 3.277 26.046 ± 2.912 26.644 ± 1.308
Spleen (g) 0.569 ± 0.075 0.638 ± 0.138 0.560 ± 0.076 0.576 ± 0.119
Spleen/TBW (ratio) 1.999 ± 0.254 2.321 ± 0.527 1.972 ± 0.310 2.090 ± 0.344
Ovaries  (g) 0.0728 ± 0.0127 0.0733 ± 0.0126 0.0746 ± 0.0158 0.0641 ± 0.0164
Ovaries/TBW (ratio) 0.2549 ± 0.0364 0.2665 ± 0.0446 0.2647 ± 0.0661 0.2318 ± 0.0471
Thymus (g) 0.2947 ± 0.0691 0.2463 ± 0.0457 0.2765 ± 0.0653 0.3144 ± 0.0705
Thymus/TBW (ratio) 1.0307 ± 0.2226 0.8913 ± 0.1435 0.9674 ± 0.2006 1.1499 ± 0.2559
Uterus and oviduct (g) 0.885 ± 0.198 0.726 ± 0.179 0.935 ± 0.308 0.744 ± 0.250
Uterus and oviduct/TBW (ratio) 3.119 ± 0.722 2.650 ± 0.718 3.281 ± 1.133 2.732 ± 1.000
Data are presented as mean ± SD. Relative organ weights (ratios) presented in the table are times 1000.
TBW  = terminal body weight.
* Signiﬁcantly different from control by Dunn Test (2 sided), p < 0.05.
** Signiﬁcantly different from control by Dunn Test after rank transformation (2 sided), 
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150 000 ppm (9947.5 mg/kg bw/day in males and 11 082.8 mg/kgig. 4. Incidences of micronucleated PCE [%] after 68 h (mean ± standard deviation).
Regarding micronucleated PCE (MN-PCE), mean frequencies for
he negative controls at both 44 and 68 h (Figs. 3 and 4) were within
he historical control limits for negative controls (0.13–0.32%). The
ean values for treated mice at 44 h were 0.22% (males) and 0.28%
females). The mean value observed in the male group was within
he range of the concurrent negative control as well as within
he historical control limits of the negative control. The mean
alue observed in the female group was statistically signiﬁcantly
ncreased compared to the concurrent negative control. However,p < 0.01.
the value was within the range of the historical control limits of the
negative control. Therefore, the signiﬁcant increase in MN-PCE in
treated females at 44 h with respect to the concurrent control only
did not meet all criteria for a positive response. For the 68 h mea-
surement, the mean values of both males and females (0.25% and
0.2%, respectively) were within the range of the concurrent neg-
ative control and historical controls. Under the conditions of the
test, pecan shell ﬁber did not cause a biologically relevant increase
in the frequency of MN-PCE. The assay was considered valid as
the MN-PCE frequencies for the negative control rats were within
the expected historical range and an adequate positive control
response was obtained (3.51% MN-PCE in males and 1.90% MN-PCE
in females).
4. Discussion
Results of the study conducted in accordance with OECD Guide-
line No. 408 indicate that the 91-day dietary no observable adverse
effect level (NOAEL) for pecan shell ﬁber in Sprague-Dawley rats isbw/day in females). A higher NOAEL in female rats (on a body-
weight basis) is consistent with the lower female bodyweights,
when compared to the male bodyweights.
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Table 5
Reverse mutation assay of pecan shell ﬁber in Salmonella typhimurium and Escherichia coli: mean number of revertants/plate.
Concentration (g) TA98 TA100 TA1535 TA1537 WP2uvrA
−S9 +S9 −S9 +S9 −S9 +S9 −S9 +S9 −S9 +S9
Experiment 1
0a 21 27 107 97 9 6 13 7 38 43
10.0  24 31 102 118 12 9 13 15 40 32
31.6  18 32 93 108 7 8 8 13 30 36
100  26 33 97 100 8 6 11 11 42 34
316  28 32 106 113 7 5 8 9 32 37
1000  26* 38* 102* 118 16* 8* 9* 8* 40* 38*
2500  26* 42* 88* 94 12* 10* 7* 10* 39* 42*
5000  40* 26* 105* 102 8* 4* 5* 8* 34* 48*
Positive control 346b 1665c 412d 1437c 539d 84c 120b 306c 289e 127c
Experiment 2
0a 18 31 87 95 16 16 11 11 46 41
3.16  16 32 93 93 19 12 10 12 39 49
10.0  16 29 91 90 18 11 9 10 42 47
31.6  23 33 92 101 13 16 8 10 39 50
100  25 31 100 109 16 10 13 8 39 46
316  30 35 111 100 19 15 7 13 50 53
1000  20 31 103 109 23 15 9† 14 46 55
2500  23* 24* 67*,† 104* 15* 15* 1*,† 10* 40* 44*
Positive control 329b 1007c 597d 1124c 586d 57c 95b 126c 572e 164c
Pecan shell ﬁber was  tested using the standardized plate incorporation assay (Experiment 1) and the pre-incubation method (Experiment 2).
*Precipitate observed.
†toxicity observed.
a Aqua dest (distilled water).
b 4-Nitro-o-phenylene diamine.
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ic 2-Aminoanthracene.
d Sodium azide.
e Methylmethanesulfonate.
All animals exposed to the test material survived to scheduled
ermination and there were no clinical signs attributed to adminis-
ration of pecan shell ﬁber. Results of ophthalmologic examinations
nd functional observational and motor activity assessments of test
nimals were comparable to controls, and there was  no effect of
ny concentration of pecan shell ﬁber on urinalysis parameters.
dministration of pecan shell ﬁber had no effect on body weight or
ody weight gain of male or female rats, with the exception of an
ncrease in body weight gain of females receiving 100 000 ppm test
aterial from Days 56–63 (p < 0.05). Food consumption of males
eceiving 100 000 or 150 000 ppm pecan shell ﬁber was higher than
ontrol, which resulted in decreased feed efﬁciency at the high dose
nly. The fact that feed efﬁciency was decreased in high dose males
s not unexpected, given the high dose of material administered
9947.5 mg/kg/day) and the fact that the ingredient is primarily
omposed of insoluble ﬁber. There was no effect of the test mate-
ial on absolute organ weights, or organ weights relative to body
eight or brain weight. All macroscopic and microscopic ﬁndings
including a renal carcinoma in one mid  dose female) were ruled
ncidental and unrelated to treatment. Renal tubular tumors have
een observed sporadically in Sprague-Dawley rats of similar age
11,15].
Statistically signiﬁcant changes in a few hematological or clin-
cal chemistry variables occurred in exposed males or females. All
hanges except the decreases in TG in females are considered unre-
ated to test material, due to lack of a dose-response, correlative
hanges in histology, and/or ﬁndings in both sexes. All hematol-
gy and clinical chemistry values were within ranges reported for
istorical controls. However, because the TG values for all exposed
roups of female animals were reduced by 22–29% compared to
ontrol, the decrease in TG is likely related to test material admin-
stration. Reductions in TG have been observed in rats consuming
igh levels of other ﬁbers such as inulin-type fructans and rice bran
2,4] and are not toxicologically relevant, because a decrease in TG
s generally thought of as a beneﬁcial effect. The lack of an effecton cholesterol is consistent with the fact that in rats, cellulose is
neutral with respect to blood cholesterol [14].
The test material was  not mutagenic in a bacterial reverse
mutation assay which tested concentrations up to the limit concen-
tration of 5000 g/plate (in the presence and absence of metabolic
activation). Although precipitation was  generally observed in plates
containing 1000 g/plate or higher concentrations of test mate-
rial in the absence of S9, it did not interfere with scoring or occur
at the four lower concentrations used in the assay (10, 31.6, 100
and 316 g/plate). Because at least ﬁve concentrations could be
evaluated (as required by the guideline), the assay is valid and
appropriate for assessing the potential of the material to cause
mutations. The results of the peripheral blood micronucleus study
in the mouse show that pecan shell ﬁber is not clastogenic or aneu-
genic at a dose of 10 000 mg/kg bw,  approximately the same daily
dose that was administered safely to rats for 91 days.
In an attempt to increase the ﬁber content of the diet, food man-
ufacturers have developed a number of different ﬁber ingredients.
These include carrot ﬁber, dried orange pulp, barley ﬁber, oat hull
ﬁber, potato ﬁber, rice bran ﬁber, corn bran ﬁber and sugar beet
ﬁber. A few of these substances (sugar beet ﬁber, corn bran ﬁber
and barley ﬁber) were tested for safety in rats. The NOAEL for pecan
shell ﬁber in the rat (15% over 13 weeks) is higher than the NOAELs
for each of these ﬁbers (10% over four weeks) [8,6,12]. Pecan shell
ﬁber provides an additional beneﬁt that several ﬁber ingredients do
not possess- high polyphenol and proanthocyanidin content, which
will aid in the preservation of food.
In conclusion, the results of the studies described in this
manuscript show that rats tolerate high levels of pecan shell ﬁber in
the diet; and suggest that the ingredient could be safely consumed
by humans at the relatively high level of intake anticipated from
use as an ingredient providing a signiﬁcant source of ﬁber in the
diet. The NOAEL in a 13-week dietary study in rats is 150 000 ppm
(9947.5 mg/kg bw/day in males and 11 082.8 mg/kg bw/day in
females), the highest dose administered. Furthermore, pecan shell
ﬁber is non-genotoxic as analyzed in a mouse peripheral blood
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icronucleus assay conducted with an oral dose approximating
he 13-week dietary NOAEL for the rat (10 000 mg/kg bw/day) and
 bacterial reverse mutation assay performed with concentrations
p to the limit concentration of 5000 g/plate.
onﬂict of interest
All authors have a ﬁnancial relationship with the sponsor of
he study and the manuscript, Southeastern Reduction Company,
aldosta, GA.
ransparency document
The Transparency document associated with this article can be
ound in the online version.
cknowledgments
The authors acknowledge the assistance of Lee Koetzner and
dete Mendes (both of Euroﬁns Product Safety Labs, Dayton, NJ),
nd Gudrun Schreib and Claudia Donath (both of Euroﬁns Bio-
harma Product Testing Munich GmbH) in conducting the studies
nd Arlene Morales and Silvia Ulm in preparing the manuscript.
eferences
[1] AAFCO, 60.110 Ground Pecan Shells. Ofﬁcial names and deﬁnitions of feed
ingredients. In 2015 Ofﬁcial Publication. Association of American Feed Control
Ofﬁcials Incorporated. 2015, p. 415.
[2] J.W. Anderson, A.E. Jones, S. Riddell-Mason, Ten different dietary ﬁbers have
signiﬁcantly different effects on serum and liver lipids of cholesterol-fed rats,
J.  Nutr. 124 (1994) 78–83.
[3] J.W. Anderson, P. Baird, R.H. Davis Jr., S. Ferreri, M.  Knudtson, A. Koraym, V.
Waters, C.L. Williams, Health beneﬁts of dietary ﬁber, Nutr. Rev. 67 (2009)
188–205.[4] M.  Beylot, Effects of inulin-type fructans on lipid metabolism in man  and in
animal models, Br. J. Nutr. 93 (2005) S163–S168.
[5] L.A. De La Rosa, E. Alvarez-Parrilla, F. Shahidi, Phenolic compounds and
antioxidant activity of kernels and shells of Mexican pecan (Carya
illinoinensis), J. Agric. Food Chem. 59 (2011) 152–162.ports 3 (2016) 87–97 97
[6] B. Delaney, T. Carlson, S. Frazer, T. Zheng, R. Hess, K. Ostergren, K. Kierzek, J.
Haworth, N. Knutson, K. Junker, D. Jonker, Evaluation of the toxicity of
concentrated barley -glucan in a 28-day feeding study in Wistar rats, Food
Chem. Toxicol. 41 (2003) 477–487.
[7] A.C.P. Do Prado, A.M. Aragão, R. Fett, J.M. Block, Antioxidant properties of
Pecan nut [Carya illinoinensis (Wangenh.) C. Koch] shell infusion, Grasas y
Aceites 60 (2009) 330–335.
[8] G. Dongowski, R. Plass, D.W.R. Bleyl, Biochemical parameters of rats fed
dietary ﬁber preparation from sugar beet, Zeitschrift fur Lebensmittel
-Untersuchung und -Forschung 206 (1998) 393–398.
[9] FDA, Substances Generally Recognized as Safe; Proposed Rule. Federal
Register Volume 62, Number 74 (Thursday, April 17, 1997). From the Federal
Register Online via the Government Printing Ofﬁce [FR Doc No: 97-9706].
http://www.gpo.gov/fdsys/pkg/FR-1997-04-17/html/97-9706.htm,  1997 (site
visited November 23, 2015).
10] W.J. Florkowski, J.C. Purcell, E.E. Hubbard, Importance for the U. S. pecan
industry of communicating about quality, HortScience 27 (1992) 462–464.
11] W.C. Hall, B. Elder, C.L. Walker, S. Cai, D.G. Peters, D.G. Goodman, B.M. Ulland,
J.F.  Borzelleca, Spontaneous renal tubular hyperplastic and neoplastic lesions
in  three Sprague-Dawley rats from a 90-day toxicity study, Toxicol. Pathol. 35
(2007) 233–241.
12] Y. Hu, Z. Wang, S. Xu, Corn bran dietary ﬁber modiﬁed by xylanase improves
the mRNA expression of genes involved in lipids metabolism in rats, Food
Chem. 109 (2008) 499–505.
13] IOM, Dietary, functional and total ﬁber, in: Dietary Reference Intakes for
Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino
Acids, National Academies Press, Washington, DC, 2005, pp. 339–371.
14] M.  Krzysik, H. Grajeta, A. Prescha, R. Weber, Effect of cellulose, pectin and
chromium (III) on lipid and carbohydrate metabolism in rats, J. Trace Elem.
Med. Biol. 25 (2011) 97–102.
15] A. Lanzoni, A. Piaia, J. Everitt, I. Faustinelli, R. Defazio, L. Cavaliere, P. Cristofori,
Early onset of spontaneous renal preneoplastic and neoplastic lesions in
young conventional rats in toxicity studies, Toxicol. Pathol. 35 (2007)
589–593.
16] J. Slavin, Fiber and prebiotics: mechanisms and health beneﬁts, Nutrients 5
(2013) 1417–1435.
17] USDA, Dietary Guidelines for Americans 2010 http://www.cnpp.usda.gov/
sites/default/ﬁles/dietary guidelines for americans/PolicyDoc.pdf, 2010 (site
visited October 2, 2015).
18] USDA, Noncitrus fruits and nuts 2014 summary http://usda.mannlib.cornell.
edu/usda/current/NoncFruiNu/NoncFruiNu-07-17-2015.pdf, 2015 (site
visited October 19, 2015).Portoghese, I.M. Rietjens, R.L. Smith, T.B. Adams, L.C. Gavin, M.M.  McZGowen,
M.C. Williams, GRAS ﬂavoring substances 23. The 23rd publication by the
FEMA expert panel presents safety and usage data on 174 new generally
recognized as safe ﬂavoring ingredients, Food Technol. (2007) 22–49.
